These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
214 related articles for article (PubMed ID: 33230203)
1. ERICH3: vesicular association and antidepressant treatment response. Liu D; Zhuang Y; Zhang L; Gao H; Neavin D; Carrillo-Roa T; Wang Y; Yu J; Qin S; Kim DC; Liu E; Nguyen TTL; Biernacka JM; Kaddurah-Daouk R; Dunlop BW; Craighead WE; Mayberg HS; Binder EB; Frye MA; Wang L; Weinshilboum RM Mol Psychiatry; 2021 Jun; 26(6):2415-2428. PubMed ID: 33230203 [TBL] [Abstract][Full Text] [Related]
2. Selective Serotonin Reuptake Inhibitor Pharmaco-Omics: Mechanisms and Prediction. Nguyen TTL; Liu D; Ho MF; Athreya AP; Weinshilboum R Front Pharmacol; 2020; 11():614048. PubMed ID: 33510640 [TBL] [Abstract][Full Text] [Related]
3. TSPAN5, ERICH3 and selective serotonin reuptake inhibitors in major depressive disorder: pharmacometabolomics-informed pharmacogenomics. Gupta M; Neavin D; Liu D; Biernacka J; Hall-Flavin D; Bobo WV; Frye MA; Skime M; Jenkins GD; Batzler A; Kalari K; Matson W; Bhasin SS; Zhu H; Mushiroda T; Nakamura Y; Kubo M; Wang L; Kaddurah-Daouk R; Weinshilboum RM Mol Psychiatry; 2016 Dec; 21(12):1717-1725. PubMed ID: 26903268 [TBL] [Abstract][Full Text] [Related]
4. The ERICH3 rs11580409 polymorphism is associated with 6-month antidepressant response in depressed patients. Chappell K; Colle R; Ait Tayeb AEK; Bouligand J; El-Asmar K; Deflesselle E; Fève B; Becquemont L; Corruble E; Verstuyft C Prog Neuropsychopharmacol Biol Psychiatry; 2022 Dec; 119():110608. PubMed ID: 35878676 [TBL] [Abstract][Full Text] [Related]
5. Pharmacogenomics-Driven Prediction of Antidepressant Treatment Outcomes: A Machine-Learning Approach With Multi-trial Replication. Athreya AP; Neavin D; Carrillo-Roa T; Skime M; Biernacka J; Frye MA; Rush AJ; Wang L; Binder EB; Iyer RK; Weinshilboum RM; Bobo WV Clin Pharmacol Ther; 2019 Oct; 106(4):855-865. PubMed ID: 31012492 [TBL] [Abstract][Full Text] [Related]
6. Plasma serotonin levels are associated with antidepressant response to SSRIs. Holck A; Wolkowitz OM; Mellon SH; Reus VI; Nelson JC; Westrin Å; Lindqvist D J Affect Disord; 2019 May; 250():65-70. PubMed ID: 30831543 [TBL] [Abstract][Full Text] [Related]
7. The International SSRI Pharmacogenomics Consortium (ISPC): a genome-wide association study of antidepressant treatment response. Biernacka JM; Sangkuhl K; Jenkins G; Whaley RM; Barman P; Batzler A; Altman RB; Arolt V; Brockmöller J; Chen CH; Domschke K; Hall-Flavin DK; Hong CJ; Illi A; Ji Y; Kampman O; Kinoshita T; Leinonen E; Liou YJ; Mushiroda T; Nonen S; Skime MK; Wang L; Baune BT; Kato M; Liu YL; Praphanphoj V; Stingl JC; Tsai SJ; Kubo M; Klein TE; Weinshilboum R Transl Psychiatry; 2015 Apr; 5(4):e553. PubMed ID: 25897834 [TBL] [Abstract][Full Text] [Related]
8. Are antidepressant drugs that combine serotonergic and noradrenergic mechanisms of action more effective than the selective serotonin reuptake inhibitors in treating major depressive disorder? A meta-analysis of studies of newer agents. Papakostas GI; Thase ME; Fava M; Nelson JC; Shelton RC Biol Psychiatry; 2007 Dec; 62(11):1217-27. PubMed ID: 17588546 [TBL] [Abstract][Full Text] [Related]
9. Genetic dysfunction of serotonin 2A receptor hampers response to antidepressant drugs: A translational approach. Qesseveur G; Petit AC; Nguyen HT; Dahan L; Colle R; Rotenberg S; Seif I; Robert P; David D; Guilloux JP; Gardier AM; Verstuyft C; Becquemont L; Corruble E; Guiard BP Neuropharmacology; 2016 Jun; 105():142-153. PubMed ID: 26764241 [TBL] [Abstract][Full Text] [Related]
10. Female sexual dysfunction in patients with major depressive disorder (MDD) treated with selective serotonin reuptake inhibitor (SSRI) and its association with serotonin 2A-1438 G/A single nucleotide polymorphisms. Masiran R; Sidi H; Mohamed Z; Mohd Nazree NE; Nik Jaafar NR; Midin M; Das S; Mohamed Saini S J Sex Med; 2014 Apr; 11(4):1047-1055. PubMed ID: 24533444 [TBL] [Abstract][Full Text] [Related]
11. Altered serotonergic circuitry in SSRI-resistant major depressive disorder patient-derived neurons. Vadodaria KC; Ji Y; Skime M; Paquola AC; Nelson T; Hall-Flavin D; Heard KJ; Fredlender C; Deng Y; Elkins J; Dani K; Le AT; Marchetto MC; Weinshilboum R; Gage FH Mol Psychiatry; 2019 Jun; 24(6):808-818. PubMed ID: 30903001 [TBL] [Abstract][Full Text] [Related]
12. Systems Approach to Identify Common Genes and Pathways Associated with Response to Selective Serotonin Reuptake Inhibitors and Major Depression Risk. Srivastava A; Singh P; Gupta H; Kaur H; Kanojia N; Guin D; Sood M; Chadda RK; Yadav J; Vohora D; Saso L; Kukreti R Int J Mol Sci; 2019 Apr; 20(8):. PubMed ID: 31018568 [TBL] [Abstract][Full Text] [Related]
13. Comparison of agomelatine and selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors in major depressive disorder: A meta-analysis of head-to-head randomized clinical trials. Huang KL; Lu WC; Wang YY; Hu GC; Lu CH; Lee WY; Hsu CC Aust N Z J Psychiatry; 2014 Jul; 48(7):663-71. PubMed ID: 24604920 [TBL] [Abstract][Full Text] [Related]
14. Edivoxetine compared to placebo as adjunctive therapy to selective serotonin reuptake inhibitors in the prevention of symptom re-emergence in major depressive disorder. Oakes TM; Dellva MA; Waterman K; Greenbaum M; Poppe C; Goldberger C; Ahl J; Perahia DG Curr Med Res Opin; 2015 Jun; 31(6):1179-89. PubMed ID: 25894953 [TBL] [Abstract][Full Text] [Related]
15. Comparison of adjunctive use of aripiprazole with bupropion or selective serotonin reuptake inhibitors/serotonin-norepinephrine reuptake inhibitors: analysis of patients beginning adjunctive treatment in a 52-week, open-label study. Clayton AH; Baker RA; Sheehan JJ; Cain ZJ; Forbes RA; Marler SV; Marcus R; Berman RM; Thase ME BMC Res Notes; 2014 Jul; 7():459. PubMed ID: 25037144 [TBL] [Abstract][Full Text] [Related]
16. Role of the serotonin transporter gene locus in the response to SSRI treatment of major depressive disorder in late life. Seripa D; Pilotto A; Paroni G; Fontana A; D'Onofrio G; Gravina C; Urbano M; Cascavilla L; Paris F; Panza F; Padovani A; Pilotto A J Psychopharmacol; 2015 May; 29(5):623-33. PubMed ID: 25827644 [TBL] [Abstract][Full Text] [Related]
17. A meta-analysis of clinical trials comparing milnacipran, a serotonin--norepinephrine reuptake inhibitor, with a selective serotonin reuptake inhibitor for the treatment of major depressive disorder. Papakostas GI; Fava M Eur Neuropsychopharmacol; 2007 Jan; 17(1):32-6. PubMed ID: 16762534 [TBL] [Abstract][Full Text] [Related]
18. [Fluoxetine: an update of its use in major depressive disorder in adults]. Gourion D; Perrin E; Quintin P Encephale; 2004; 30(4):392-9. PubMed ID: 15597466 [TBL] [Abstract][Full Text] [Related]
19. Serotonin-induced hyperactivity in SSRI-resistant major depressive disorder patient-derived neurons. Vadodaria KC; Ji Y; Skime M; Paquola A; Nelson T; Hall-Flavin D; Fredlender C; Heard KJ; Deng Y; Le AT; Dave S; Fung L; Li X; Marchetto MC; Weinshilboum R; Gage FH Mol Psychiatry; 2019 Jun; 24(6):795-807. PubMed ID: 30700803 [TBL] [Abstract][Full Text] [Related]
20. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. Kim H; Lim SW; Kim S; Kim JW; Chang YH; Carroll BJ; Kim DK JAMA; 2006 Oct; 296(13):1609-18. PubMed ID: 17018806 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]